Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Respiration Année : 2016

Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension

Résumé

Patients treated for pulmonary arterial hypertension (PAH) frequently receive vitamin K antagonists (VKAs) for PAH or validated indications (such as atrial fibrillation or venous thromboembolism). In these latter indications, VKAs are challenged by direct oral anticoagulants (DOAs). Decreased dosage of DOAs has been proposed in patients at risk of bioaccumulation.

Dates et versions

hal-01963174 , version 1 (21-12-2018)

Identifiants

Citer

Laurence Gabriel, Xavier Delavenne, Pierrick Bedouch, Chahéra Khouatra, Hélène Bouvaist, et al.. Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. Respiration, 2016, 91 (4), pp.307-315. ⟨10.1159/000445122⟩. ⟨hal-01963174⟩
1338 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More